NASDAQ:AKCA - Akcea Therapeutics Stock Price, Price Target & More

$26.42 +2.35 (+9.76 %)
(As of 04/20/2018 12:24 PM ET)
Previous Close$24.07
Today's Range$24.34 - $26.90
52-Week Range$8.10 - $33.99
Volume175,906 shs
Average Volume339,497 shs
Market Capitalization$1.61 billion
P/E Ratio-11.36
Dividend YieldN/A
BetaN/A

About Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics logoAkcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Debt-to-Equity RatioN/A
Current Ratio3.30%
Quick Ratio3.30%

Price-To-Earnings

Trailing P/E Ratio-11.36
Forward P/E Ratio-20.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$55.21 million
Price / Sales31.93
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book9.79

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees100
Outstanding Shares66,720,000

How to Become a New Pot Stock Millionaire

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics (NASDAQ:AKCA) posted its quarterly earnings results on Monday, February, 26th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.03. The firm earned $18.04 million during the quarter, compared to analyst estimates of $15.48 million. View Akcea Therapeutics' Earnings History.

What price target have analysts set for AKCA?

4 analysts have issued 1 year price targets for Akcea Therapeutics' shares. Their predictions range from $20.00 to $30.00. On average, they anticipate Akcea Therapeutics' stock price to reach $26.6667 in the next twelve months. View Analyst Ratings for Akcea Therapeutics.

Who are some of Akcea Therapeutics' key competitors?

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the folowing people:
  • Ms. Paula Soteropoulos, CEO, Pres & Director (Age 50)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
  • Dr. Louis St. Laurence O'Dea MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
  • D. Wade Walke Ph.D., VP of Corp. Communications & Investor Relations

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Has Akcea Therapeutics been receiving favorable news coverage?

News stories about AKCA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the company an impact score of 46.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $26.42.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.61 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]


MarketBeat Community Rating for Akcea Therapeutics (AKCA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akcea Therapeutics (NASDAQ:AKCA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Akcea Therapeutics in the last 12 months. Their average twelve-month price target is $26.6667, suggesting that the stock has a possible upside of 0.93%. The high price target for AKCA is $30.00 and the low price target for AKCA is $20.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.6667$26.6667$24.00$23.6667
Price Target Upside: 0.93% upside14.56% downside44.49% upside58.84% upside

Akcea Therapeutics (NASDAQ:AKCA) Consensus Price Target History

Price Target History for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ:AKCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Wells FargoReiterated RatingOutperform -> Market Perform$20.00HighView Rating Details
3/16/2018Stifel NicolausBoost Price TargetBuy -> Buy$20.00 -> $30.00HighView Rating Details
2/27/2018BMO Capital MarketsBoost Price TargetPositive -> Outperform$25.00 -> $30.00HighView Rating Details
2/27/2018CowenDowngradeOutperform -> Market PerformHighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Akcea Therapeutics (NASDAQ:AKCA) Earnings History and Estimates Chart

Earnings by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ:AKCA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.32 EPS
Next Year EPS Consensus Estimate: $1.19 EPS

Akcea Therapeutics (NASDAQ AKCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018Q4 2017($0.23)($0.26)$15.48 million$18.04 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.21)($0.18)$15.48 million$13.45 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.27)$14.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Akcea Therapeutics (NASDAQ:AKCA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Akcea Therapeutics (NASDAQ AKCA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.70%
Institutional Ownership Percentage: 29.10%
Insider Trading History for Akcea Therapeutics (NASDAQ:AKCA)
Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ AKCA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Ionis Pharmaceuticals IncMajor ShareholderBuy10,666,666$18.75$199,999,987.5053,447,879View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.0028,884,540View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akcea Therapeutics (NASDAQ AKCA) News Headlines

Source:
DateHeadline
Akcea Therapeutics (AKCA) Major Shareholder Ionis Pharmaceuticals Inc Purchases 10,666,666 SharesAkcea Therapeutics (AKCA) Major Shareholder Ionis Pharmaceuticals Inc Purchases 10,666,666 Shares
www.americanbankingnews.com - April 19 at 7:18 PM
Akcea Therapeutics, Inc.: Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTRAkcea Therapeutics, Inc.: Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
www.finanznachrichten.de - April 17 at 9:50 AM
Sarah Boyce Joins Akcea Therapeutics as President and Member of the Board of DirectorsSarah Boyce Joins Akcea Therapeutics as President and Member of the Board of Directors
finance.yahoo.com - April 17 at 9:50 AM
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTRAkcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
finance.yahoo.com - April 17 at 9:50 AM
Akcea Therapeutics (AKCA) Receives New Coverage from Analysts at Wells FargoAkcea Therapeutics (AKCA) Receives New Coverage from Analysts at Wells Fargo
www.americanbankingnews.com - April 12 at 9:00 PM
Akcea Therapeutics (AKCA) Research Coverage Started at Stifel NicolausAkcea Therapeutics (AKCA) Research Coverage Started at Stifel Nicolaus
www.americanbankingnews.com - April 12 at 9:00 PM
Akcea Therapeutics (AKCA) Now Covered by CowenAkcea Therapeutics (AKCA) Now Covered by Cowen
www.americanbankingnews.com - April 12 at 9:00 PM
Akcea Therapeutics (AKCA) Receives Consensus Recommendation of "Buy" from AnalystsAkcea Therapeutics (AKCA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 9 at 1:43 AM
Akcea Therapeutics (AKCA) Stock Rating Lowered by BidaskClubAkcea Therapeutics (AKCA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 6 at 11:51 AM
How Worried Should Alnylam and Ionis Really Be About Pfizers New Data?How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
finance.yahoo.com - April 3 at 4:29 PM
Akcea Therapeutics (AKCA) Stock Rating Reaffirmed by Stifel NicolausAkcea Therapeutics (AKCA) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - April 1 at 4:16 PM
Akcea Therapeutics (AKCA) Upgraded to "Buy" by BidaskClubAkcea Therapeutics (AKCA) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 9:57 AM
Akcea Therapeutics (AKCA) Stock Rating Lowered by Wells FargoAkcea Therapeutics (AKCA) Stock Rating Lowered by Wells Fargo
www.americanbankingnews.com - March 24 at 10:39 PM
Akcea Therapeutics (AKCA) Cut to Hold at Stifel NicolausAkcea Therapeutics (AKCA) Cut to Hold at Stifel Nicolaus
www.americanbankingnews.com - March 24 at 10:02 PM
Cowen Lowers Akcea Therapeutics (AKCA) to Market PerformCowen Lowers Akcea Therapeutics (AKCA) to Market Perform
www.americanbankingnews.com - March 24 at 10:02 PM
BMO Capital Markets Boosts Akcea Therapeutics (AKCA) Price Target to $30.00BMO Capital Markets Boosts Akcea Therapeutics (AKCA) Price Target to $30.00
www.americanbankingnews.com - March 24 at 9:28 PM
Akcea Therapeutics (AKCA) Upgraded at BidaskClubAkcea Therapeutics (AKCA) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 1:37 PM
Akcea Therapeutics (AKCA) Upgraded to Strong-Buy at BidaskClubAkcea Therapeutics (AKCA) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 23 at 9:00 PM
Akcea Therapeutics, Inc.: MHRA Grants UK Patients Early Access to Akcea Therapeutics Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)Akcea Therapeutics, Inc.: MHRA Grants UK Patients Early Access to Akcea Therapeutics' Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)
www.finanznachrichten.de - March 22 at 9:45 AM
MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)
globenewswire.com - March 22 at 9:45 AM
MHRA Grants UK Patients Early Access to Akcea Therapeutics ... - NasdaqMHRA Grants UK Patients Early Access to Akcea Therapeutics ... - Nasdaq
www.nasdaq.com - March 21 at 10:41 AM
MHRA Grants UK Patients Early Access to Akcea Therapeutics Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)MHRA Grants UK Patients Early Access to Akcea Therapeutics' Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)
finance.yahoo.com - March 21 at 10:41 AM
Akcea Therapeutics (NASDAQ:AKCA) Downgraded By Wells Fargo ... - BenzingaAkcea Therapeutics (NASDAQ:AKCA) Downgraded By Wells Fargo ... - Benzinga
www.benzinga.com - March 20 at 4:18 PM
Akcea Therapeutics Downgraded By Wells Fargo After Huge RunAkcea Therapeutics Downgraded By Wells Fargo After Huge Run
finance.yahoo.com - March 20 at 9:43 AM
Traders Purchase Large Volume of Akcea Therapeutics Call Options (AKCA)Traders Purchase Large Volume of Akcea Therapeutics Call Options (AKCA)
www.americanbankingnews.com - March 20 at 6:42 AM
Akcea Therapeutics Target of Unusually Large Options Trading (AKCA)Akcea Therapeutics Target of Unusually Large Options Trading (AKCA)
www.americanbankingnews.com - March 20 at 6:40 AM
Zacks Investment Research Upgrades Akcea Therapeutics (AKCA) to "Hold"Zacks Investment Research Upgrades Akcea Therapeutics (AKCA) to "Hold"
www.americanbankingnews.com - March 19 at 4:30 PM
Akcea Therapeutics (AKCA) Given Market Perform Rating at Wells FargoAkcea Therapeutics (AKCA) Given Market Perform Rating at Wells Fargo
www.americanbankingnews.com - March 19 at 11:12 AM
Akcea Therapeutics Inc. (AKCA) Is Suring After Teaming With Ionis - NasdaqAkcea Therapeutics Inc. (AKCA) Is Suring After Teaming With Ionis - Nasdaq
www.nasdaq.com - March 17 at 9:43 AM
Akcea Therapeutics (AKCA) Price Target Raised to $30.00 at Stifel NicolausAkcea Therapeutics (AKCA) Price Target Raised to $30.00 at Stifel Nicolaus
www.americanbankingnews.com - March 16 at 6:06 PM
Why Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is DroppingWhy Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is Dropping
finance.yahoo.com - March 15 at 4:54 PM
Akcea Therapeutics (AKCA) Lifted to "Outperform" at Wells Fargo & CoAkcea Therapeutics (AKCA) Lifted to "Outperform" at Wells Fargo & Co
www.americanbankingnews.com - March 15 at 3:38 PM
Akcea Therapeutics Inc (AKCA) Receives Consensus Recommendation of "Hold" from AnalystsAkcea Therapeutics Inc (AKCA) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 15 at 1:04 AM
Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & ExpoPositive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
finance.yahoo.com - March 12 at 5:29 PM
Akcea Therapeutics to Present at Upcoming Investor ConferencesAkcea Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 6 at 9:20 AM
Comparing BioDelivery Sciences International (BDSI) & Akcea Therapeutics (AKCA)Comparing BioDelivery Sciences International (BDSI) & Akcea Therapeutics (AKCA)
www.americanbankingnews.com - March 2 at 4:34 PM
Altrinsic Global Advisors LLC Acquires 25,000 Shares of Akcea Therapeutics Inc (AKCA)Altrinsic Global Advisors LLC Acquires 25,000 Shares of Akcea Therapeutics Inc (AKCA)
www.americanbankingnews.com - March 2 at 4:10 AM
Akcea Therapeutics (AKCA) Downgraded by Zacks Investment ResearchAkcea Therapeutics (AKCA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 1 at 6:36 PM
More Commercial Revenue on Its Way for Ionis PharmaceuticalsMore Commercial Revenue on Its Way for Ionis Pharmaceuticals
finance.yahoo.com - March 1 at 4:48 PM
Akcea Therapeutics reports 4Q lossAkcea Therapeutics reports 4Q loss
finance.yahoo.com - February 27 at 9:31 AM
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017 Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017 
finance.yahoo.com - February 26 at 4:56 PM
Akcea Therapeutics (AKCA) Lowered to "Hold" at BidaskClubAkcea Therapeutics (AKCA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - February 21 at 11:10 PM
Akcea Therapeutics Inc (AKCA) Given Average Recommendation of "Buy" by BrokeragesAkcea Therapeutics Inc (AKCA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 18 at 1:30 AM
Akcea Therapeutics (AKCA) Announces FDA Panel Meeting to Review Volanesorsen as Treatment for Familial Chylomicronemia SyndromeAkcea Therapeutics (AKCA) Announces FDA Panel Meeting to Review Volanesorsen as Treatment for Familial Chylomicronemia Syndrome
www.streetinsider.com - February 16 at 9:09 AM
Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia SyndromeAkcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome
finance.yahoo.com - February 15 at 4:34 PM
Akcea Therapeutics Inc (AKCA) Sees Large Increase in Short InterestAkcea Therapeutics Inc (AKCA) Sees Large Increase in Short Interest
www.americanbankingnews.com - February 9 at 4:58 PM
Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRxAkcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx
finance.yahoo.com - February 7 at 9:12 AM
Akcea Therapeutics Inc (AKCA) Receives Average Rating of "Buy" from AnalystsAkcea Therapeutics Inc (AKCA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Akcea Therapeutics (AKCA) Raised to "Hold" at BidaskClubAkcea Therapeutics (AKCA) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - January 20 at 12:33 PM
BidaskClub Downgrades Akcea Therapeutics (AKCA) to SellBidaskClub Downgrades Akcea Therapeutics (AKCA) to Sell
www.americanbankingnews.com - January 6 at 8:52 PM

SEC Filings

Akcea Therapeutics (NASDAQ:AKCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akcea Therapeutics (NASDAQ:AKCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akcea Therapeutics (NASDAQ AKCA) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.